BP 897 

BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM)^[1].

BP 897 also displays low affinities at D1 and D4 receptors (K_i=3 and 0.3 μM, respectively), as well as at α1 and α2 adrenergic receptors (K_i=60 and 83 nM, respectively), 5HT1A and 5HT7 receptors (K_i=84 and 345 nM, respectively), and negligible affinities (K_i>1 μM) atmuscarinic, histamine and opiate receptors^[1].
In NG 108-15 cells expressing the human D3 receptor, BP 897 inhibits forskolin-induced cyclic AMP accumulation with an EC₅₀ of 1 nM. BP 897 activates mitogenesis and this response is antagonized by the preferential D3 receptor antagonist Nafadotride (1 μM). BP 897 also partially antagonized the response induced by quinpirole (10 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

417.54

C₂₆H₃₁N₃O₂

192384-87-5

COC1=C(N2CCN(CCCCNC(C3=CC4=C(C=CC=C4)C=C3)=O)CC2)C=CC=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pilla M, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist [published correction appears in Nature 1999 Sep 23;401(6751):403]. Nature. 1999;400(6742):371-375.  [Content Brief]